PCN33 MAPPING FACT-PAND EORTC QLQ-C30TOTHE EQ-5D HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER PATIENTS  by Wu, E et al.
A114 Abstracts
European countries (France, Germany, Italy, UK). Additionally
it was tested which inﬂuence a generic product would have on
the relative importance of product attributes. RESULTS: The
conjoint analyses resulted in the fact that there were major dif-
ferences between the relative importance of attributes between
physicians in Europe and the US. In the US efﬁcacy was the most
preferable attribute. Even when a generic drug would enter the
market efﬁcacy would still be the most important attribute—on
a lower level than for the “branded” product market but still the
most important. In Europe the most important attribute was 
the cost. Even when a generic product would enter the market
the costs would be the most important factor. CONCLUSIONS:
The discussions about the increasing health care costs across
Europe could have a major impact on the potential prescribing
behavior of physicians. Even in the breast cancer market which
is highly under public view the pressure on health care budget is
changing the relative importance of products. In the US where
these discussions are not as intensive as in Europe this conclu-
sion cannot be found.
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OBJECTIVES: To construct and validate a prediction model of
health utility (EQ-5D) for metastatic hormone-refractory prostate
cancer (HRPCA) patients using cancer-speciﬁc health-related
quality of life (HRQL) measures. METHODS: Data were
obtained from a multicenter, multinational observational study
of metastatic HRPCA patients conducted during 2002–2004. In
addition to clinical and resource utilization, health utility (EQ-
5D) and HRQL (Functional Assessment of Cancer Therapy—
Prostate [FACT-P] and European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire [EORTC
QLQ-C30]) data were collected. Predictive validity of ordinary
least square (OLS), Tobit, and median regressions of various
model speciﬁcations were tested using cross-validation samples.
The selected speciﬁcation was then further reﬁned and tested for
alternative model speciﬁcations and restrictions. RESULTS: OLS
regression with both HRQL measures as individual components
and patient demographics was the best performing model. It
explained 58.2% of the observed EQ-5D variation in the valida-
tion sample. A model including only the prostate cancer–speciﬁc
HRQL measure, FACT-P, explained 53.5% of the observed EQ-
5D variation. Both models have good ability to distinguish
patients with high health utility from those with low utility for
cutoff points between the 20th and 80th percentiles of observed
EQ-5D values. CONCLUSIONS: The prediction models devel-
oped have good predictive validity. These algorithms enable
researchers to translate cancer–speciﬁc HRQL measures to health
utility in metastatic HRPCA patients. The ﬁndings will help
perform utility adjustments in cost-utility analyses.
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OBJECTIVES: The purpose of this validation study was to test
the accuracy and acceptability of an Internet-based questionnaire
(Qx) assessing health-related quality of life (HRQoL) among
subjects in CaPSURE, a longitudinal study of health outcomes
among men with prostate cancer. METHODS: Active partici-
pants were sent a ﬂyer with their usual bi-annual Qx offering the
opportunity to test the new Internet version and were paid $25
for their participation. Volunteers were randomized to one of
two Qx administration groups (paper-then-Internet or Internet-
then-paper). The SF-36 and the UCLA Prostate Cancer Index
(PCI) comprised the HRQoL Qx. A 10-item survey designed to
measure patient preference of administration was administered
after completion of both modalities. Descriptive statistics,
Pearson correlation coefﬁcients, and percent agreement were
used to assess comparability between these two methods of
administration. RESULTS: A convenience sample of 245 subjects
volunteered to participate; 209 (85%) completed both paper and
online Qx. Subject median age was 63 years-old (range 46–83).
The majority of respondents were white (97%), college educated
(66%) and had an income of >$75,000/year (46%). With few
exceptions, correlation coefﬁcients for the HRQoL multi-level
items were high (0.66–0.97) and the percent agreement for
yes/no items was also very high (>0.89). Subjects rated both
methods of administration favorably, although the Internet was
rated as somewhat more convenient and faster to complete.
There were no differences between the two versions on respon-
dent ratings for ease of reading, ease of answer completion, con-
fusion or stress. 70% preferred the Internet mode; 21% had no
preference and 9% preferred paper. CONCLUSIONS: Adminis-
tration of the HRQoL Qx, including SF-36 and PCI domains,
demonstrated a high correlation between the Internet and the
paper-and-pencil methods. The Internet was a well-accepted
mode among this select group of older men with prostate cancer.
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OBJECTIVE: Develop/validate a quality of life questionnaire for
capturing the unique spectrum of symptoms and impact on phys-
ical/psychological functioning related to neuroendocrine tumors
and eliciting patients’ own perceptions of their illness, providing
a guide to therapeutic options. METHODS: A total of 103 sub-
jects from a Philadelphia Neuroendocrine Tumor (NET) Con-
ference completed the QOL-NET. Seventy-two subjects were
females (mean age 56.29 + 1.03 years); and 27 were males (mean
age 54.89 + 0.95 years). The population was predominately Cau-
casian (92.2%). On the data, we performed an exploratory
factor analysis using a forced 7-factor varimax rotation. A
descriptive statistical analysis was completed on the total QOL
score and seven factors. Internal consistency was estimated using
Cronbach’s alpha coefﬁcient. Test-retest reliability over a 4–6
week period was assessed by a pairwise t-test on data from a
subset of 20 subjects. RESULTS: All 72 questions loaded into
the 7 domains, which we called: Factor 1 = Depression; Factor
2 = Flushing; Factor 3 = Respiratory; Factor 4 = Gastrointesti-
nal; Factor 5 = Cardiovascular; Factor 6 = Physical Functioning;
Factor 7 = Positive Attitude. Seventy-two items on the forced
seven factor solution accounted for 71.74% of the variance. If
items loaded with a score ≥0.35 on more than one factor, the
highest loading was used. The summary statistics for the Total
QOL and each domain: Total QOL, 76.80 ± 4.80; Factor 1,
